FDA Takes Significant Steps Toward Phasing Out Animal Testing

In a development that animal welfare advocates have long awaited, the US Food and Drug Administration has been making significant strides toward reducing and eventually phasing out animal testing for drug approvals. Over the past few years, the FDA has gradually embraced alternative testing methods, and 2025 marked a turning point in this transition.

The shift has been driven by remarkable advances in technology. Organ-on-a-chip devices — tiny microfluidic systems that replicate the functions of human organs — can now simulate how drugs interact with human biology more accurately than animal models in many cases. AI-powered computational models can predict drug toxicity and efficacy by analyzing vast databases of molecular interactions. 3D-printed tissue models and stem cell-derived organoids provide additional ways to test drug safety without using animals.

“Over the past few years, the FDA has gradually embraced alternative testing methods, and 2025 marked a turning point in this transition.”

In 2023, the FDA Modernization Act 2.0 officially removed the requirement that drugs must be tested on animals before human clinical trials, opening the door for alternative methods. Since then, the agency has been steadily expanding its acceptance of non-animal data in drug applications, and several major pharmaceutical companies have begun incorporating these methods into their development pipelines.

The implications extend beyond animal welfare. Animal testing has long been recognized as imperfect — roughly 95% of drugs that pass animal tests fail in human clinical trials, suggesting that animal models often don't accurately predict human responses. Alternative methods that use human cells and tissues may actually provide better safety data, potentially reducing the time and cost of bringing new drugs to market.

For the millions of animals used in research each year — primarily mice, rats, rabbits, and primates — this shift represents a historic change. Animal welfare organizations have praised the FDA's direction while emphasizing that continued investment in alternative technologies is essential to complete the transition. The goal is not just to reduce animal testing but to build a regulatory framework where the best available science guides drug safety assessment — and increasingly, that science points toward human-relevant alternatives.